Your browser doesn't support javascript.
loading
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park, Joon Seok; Gazzaniga, Francesca S; Wu, Meng; Luthens, Amalia K; Gillis, Jacob; Zheng, Wen; LaFleur, Martin W; Johnson, Sarah B; Morad, Golnaz; Park, Elizabeth M; Zhou, Yifan; Watowich, Stephanie S; Wargo, Jennifer A; Freeman, Gordon J; Kasper, Dennis L; Sharpe, Arlene H.
Afiliación
  • Park JS; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Gazzaniga FS; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Wu M; Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
  • Luthens AK; Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • Gillis J; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Zheng W; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • LaFleur MW; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Johnson SB; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Morad G; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Park EM; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhou Y; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Watowich SS; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wargo JA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Freeman GJ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kasper DL; Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sharpe AH; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nature ; 617(7960): 377-385, 2023 05.
Article en En | MEDLINE | ID: mdl-37138075
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Microbiota / Inmunoterapia / Melanoma Tipo de estudio: Guideline / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Microbiota / Inmunoterapia / Melanoma Tipo de estudio: Guideline / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos